DE60044303D1 - Nicht-immunsuppresives hiv tat-protein - Google Patents

Nicht-immunsuppresives hiv tat-protein

Info

Publication number
DE60044303D1
DE60044303D1 DE60044303T DE60044303T DE60044303D1 DE 60044303 D1 DE60044303 D1 DE 60044303D1 DE 60044303 T DE60044303 T DE 60044303T DE 60044303 T DE60044303 T DE 60044303T DE 60044303 D1 DE60044303 D1 DE 60044303D1
Authority
DE
Germany
Prior art keywords
lentivirus
tat
disclosed
immunosuppresive
tat protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60044303T
Other languages
English (en)
Inventor
David I Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NANIRX, INC., ROCKVILLE, MD., US
Original Assignee
InIst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InIst Inc filed Critical InIst Inc
Application granted granted Critical
Publication of DE60044303D1 publication Critical patent/DE60044303D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60044303T 1999-08-12 2000-08-10 Nicht-immunsuppresives hiv tat-protein Expired - Lifetime DE60044303D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14852699P 1999-08-12 1999-08-12
PCT/US2000/021920 WO2001012220A1 (en) 1999-08-12 2000-08-10 Non-immunosuppressant hiv tat

Publications (1)

Publication Number Publication Date
DE60044303D1 true DE60044303D1 (de) 2010-06-10

Family

ID=22526144

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60044303T Expired - Lifetime DE60044303D1 (de) 1999-08-12 2000-08-10 Nicht-immunsuppresives hiv tat-protein

Country Status (7)

Country Link
US (2) US6667151B1 (de)
EP (1) EP1246647B1 (de)
AT (1) ATE465754T1 (de)
AU (1) AU785258B2 (de)
CA (1) CA2398269C (de)
DE (1) DE60044303D1 (de)
WO (1) WO2001012220A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
WO2006033665A1 (en) * 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
US20070248618A1 (en) * 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
EP1279404A1 (de) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Verwendung von HIV-1 Fragmenten oder Derivaten zur Bestimmung oder Aktivierung von Antigen-präsentierenden Zellen, oder zur Abgabe von Cargo-Molekülen für Impfung oder für Behandlung von anderen Erkrankungen
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
WO2011078426A1 (ko) * 2009-12-24 2011-06-30 연세대학교 산학협력단 비만 억제 및 치료용 펩타이드
CN104981479B (zh) 2012-12-06 2021-06-01 品诺制药公司 用免疫抑制性Tat衍生多肽治疗炎症、自身免疫和神经退行性疾病
RU2695653C2 (ru) 2013-10-04 2019-07-25 Пин Фарма, Инк. Иммуностимулирующие полипептидные производные тат вич для применения в лечении рака

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522081A4 (en) * 1990-03-30 1993-06-16 Smithkline Beecham Corporation Inhibition of disease associated with immunodeficiency virus infection
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
CA2215483C (fr) * 1995-03-08 2012-01-03 Jean-Francois Zagury Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps, procede de preparation et compositions pharmaceutiques les renfermant
FR2731355B1 (fr) * 1995-03-08 1997-05-30 Neovacs Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
US20030215797A1 (en) 2003-11-20
EP1246647B1 (de) 2010-04-28
WO2001012220A1 (en) 2001-02-22
WO2001012220A9 (en) 2002-07-11
AU6631100A (en) 2001-03-13
AU785258B2 (en) 2006-12-07
EP1246647A4 (de) 2005-09-21
CA2398269C (en) 2013-04-09
EP1246647A1 (de) 2002-10-09
ATE465754T1 (de) 2010-05-15
CA2398269A1 (en) 2001-02-22
US6667151B1 (en) 2003-12-23

Similar Documents

Publication Publication Date Title
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
DE60044303D1 (de) Nicht-immunsuppresives hiv tat-protein
ATE158415T1 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
CY1113477T1 (el) Ετερολογος εκφραση πρωτεϊνων της neisseria
CY1110878T1 (el) Διαδικασιες για την μετρηση της ισχυος του glatiramer acetate
AR029759A1 (es) Variante de glucoamilasa original, una construccion de adn, un vector de expresion recombinante, una celula, un proceso para convertir almidon, uso de una variante de glucoamilasa para un proceso de fermentacion y metodo para mejorar la estabilidad termica.
DE69620877D1 (de) Arzneimittelformulierungen für il-12
WO2001077951A8 (en) System and methods for group retirement plan administration
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
NO20030856D0 (no) Membranpenetrerende peptider og anvendelse av disse
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
DK208987D0 (da) Polypeptider og antistoffer, som er karakteristiske for papillomvirus, og deres anvendelse ved diagnostiske metoder og i vacciner
DE60042209D1 (de) Enzymatische synthese von deoxyribonucleotiden
NO20031860D0 (no) Kahalaolid F
AU2001275438A1 (en) Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
ITRM920350A1 (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
TR200200802T2 (tr) Aşı
DK0491713T3 (da) Rubella El-peptider og C-peptider
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
FR2828934B1 (fr) Test de l'immunite cellulaire par des peptides fixes sur support solide
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
ES2157435T3 (es) Particulas retroviricas pseudotipadas.
IT1251961B (it) Peptidi che rappresentano permutazioni della sequenza del mastoparano
DE60045663D1 (de) Rlichem interferon-alpha

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NANIRX, INC., ROCKVILLE, MD., US

8364 No opposition during term of opposition